Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension

Canadian Journal of Ophthalmology

Volumn 40, Issue 2, 2005, Pages 161-169

  Tingey, David ^a   Bernard, Lisa M ^b   Grima, Daniel T ^b   Miller, Betsy ^c   Lam, Annette ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b i3 Global   (Canada)

^c Pharmacia Canada   (Canada)

Author keywords

Adrenergic beta antagonists; Beta blockers; Latanoprost; Ocular hypertension; Open angle glaucoma; Physicians' practice patterns

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LEVOBUNOLOL; TIMOLOL MALEATE;

ADULT; AGED; CANADA; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; GONIOSCOPY; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; OPTIC NERVE; PERIMETRY; PRESCRIPTION; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; REVIEW; SLIT LAMP; TONOMETRY; VISUAL ACUITY;

EID: 18744407879     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/S0008-4182(05)80027-4     Document Type: Article

References (24)

1. World Health Organization. Blindness and visual disability. Part II of VII: Major causes worldwide. Fact sheet N143. 1997. Available: http://www.who.org (accessed 2002 Aug 26).
2. Coyle D, Drummond M. The economic burden of glaucoma in the UK. The need for a far-sighted policy. Pharmacoeconomics 1995;7:484-9.
3. Glaucoma Panel, Preferred Practice Patterns Committee, American Academy of Ophthalmology. Preferred practice pattern: primary open-angle glaucoma. San Francisco (CA): the Academy; 1996.
4. Jay JL, Allan D. The benefit of early trabeculectomy versus conventional management in primary open angle glaucoma relative to severity of disease. Eye 1989;3:528-35.
5. Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994;101:1651-6.
6. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Am J Ophthalmol 1995;120:718-31.
7. Fluorouracil Filtering Surgery Study Group. Five-year follow-up of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol 1996;121:349-66.
8. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991;111:51-5.
9. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40.
10. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97.
11. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498-505.
12. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13.
13. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79.
14. Jönsson B. The health economics of glaucoma. In: Jönsson B, Krieglstein G, editors. Primary open-angle glaucoma: differences in international treatment patterns and costs. Oxford (England): Isis Medical Media; 1999. p. 1-9.
15. Alward WLM. Medical management of glaucoma. N Engl J Med 1998;339:1298-307.
16. Kobelt G, Jönsson L, Gerdtham U, Krieglstein GK. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 1998;236:811-21.
17. Rouland JF, Hågå A, Bengtsson S, Hedman K, Kobelt G. What triggers change of therapy? In: Jönsson B, Krieglstein G, editors. Primary open-angle glaucoma: differences in international treatment patterns and costs. Oxford (England): Isis Medical Media; 1999. p. 163-9.
18. Damji KF, Behki R, Wang L, for the Target IOP Workshop participants. Canadian perspectives in glaucoma management: setting target intraocular pressure range. Can J Ophthalmol 2003;38:189-97.
19. Dasgupta S, Oates V, Bookhart BK, Vaziri B, Schwartz GF, Mozaffari E. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care 2002;8(10 Suppl):S255-61.
20. Spooner JJ, Bullano MF, Ikeda LI, Cockerham TR, Waugh WJ, Johnson T, et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care 2002;8(10 Suppl):S262-70.
21. Shaya FT, Mullins CD, Wong W, Cho J. Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care 2002;8(10 Suppl):S271-7.
22. Diestelhorst M, Schaefer CP, Beusterien KM, Plante KM, Fain JM, Mozaffari E, et al. Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study. Eur J Ophthalmol 2003;13(Suppl 4):S21-9.
23. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol 2000;10:95-104.
24. Rouland JF, Le Pen C; ophthalmologists of the Glaucoma Study. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year. Eur J Ophthalmol 2003;13(Suppl 4):S5-20.